Analysis of HCV DAA resistance mutations in HIV and HTLV-1 superinfection cases

Not Applicable

• Conditions: Patients HCV RNA is positive, and the HIV antibody or HTLV-1 antibody-positive,

• Registration Number: JPRN-UMIN000017059
• Lead Sponsor: agasaki University Hospital

Brief Summary

HCV RNA was extracted using the remaining serum, and DAA drug resistance mutations were analyzed using direct sequencing. DAA drug resistance mutations were observed in 2 out of 6 HIV co-infected cases and in 5 out of 22 HTLV-1 co-infected cases, but the frequency of these mutations was similar to that in HCV monoinfected cases.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-13
• Study Completion: 2016-02-29
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

-Patients already that against HCV, interventions such as IFN treatment has been carried out -HCV RNA is a viral load low value is also positive, nucleotide sequence analysis is difficult cases

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-The presence or absence of HCV DAA-resistant amino acid mutations -The presence or absence of HCV NS3 area DAA-resistant amino acid mutations -The presence or absence of HCV NS5A area DAA-resistant amino acid mutations -The presence or absence of HCV NS5B area DAA-resistant amino acid mutations